$MDNA.TO

Medicenna Therapeutics Provides MDNA11 Update

Medicenna Therapeutics (MDNA.TO) said Wednesday that its lead compound MDNA11 was featured in a poster presentation describing the investigator-sponsored NEO-CYT trial at the American Society of Clinical Oncology (ASCO), annual meeting in Chicago.While surgery has been the first course of action in treating locally advanced melanoma, a recent study has shown that administering combination immunotherapy, comprised of two pre-operative cycles of ipilimumab plus nivolumab, is much more effective than the previous post-surgery standard.However, 41% of patients did not achieve a major pathologic response (meaning "NEO-CYT provides an important opportunity to evaluate MDNA11, a potentially best-in-class IL-2 superagonist, in a frontline neoadjuvant setting where immune activation may be especially impactful," said Fahar Merchant, chief executive officer. " If the tumor is still present at the time of the treatment, the immune cells 'see' more of the cancer cells. This allows the most potent anti-tumor immune cells to expand and attack the tumor and can remain active in the body for many years, preventing the tumors from recurring."Merchant noted that the NEO-CYT trial complements Medicenna's ongoing ABILITY-1 study, which is also advancing MDNA11 into earlier lines of therapy through expansion cohorts in various cancers.The company will share updates on the ABILITY-1 trial and the NEO-CYT study in the second half of this year.Medicenna shares were last seen up $0.005, to $0.425, on the Toronto Stock Exchange.Price: $0.43, Change: $+0.01, Percent Change: +1.19%

Medicenna Therapeutics Raises $4.4M Via Public Offering of Units

Medicenna Therapeutics (MDNA.TO) closed its previously announced marketed public offering of units at $0.50 apiece, for about $4.44 million, before deducting offering expenses and excluding any proceeds the company may receive from the exercise of the underlying warrants, it said on Thursday.The raising will be used to support lead programs, it added.Under the offering, MDNA issued a total of near 8.9-million units. Each unit is comprised of one common share and one-half of one common share purchase warrant of the company. Each warrant entitles the holder thereof to buy a share for $0.65 per warrant share until the date that is three years following the initial closing date of the offering.The company also entered into a separate structured financing of $8.0 million with Sorbie Bornholm LP and Sorbie Investments LLP.Shares of the company were last seen up 2.4% at $0.435 on the Toronto Stock Exchange.Price: $0.44, Change: $+0.01, Percent Change: +2.35%

Medicenna Therapeutics Finalizes Terms of its Public Offering of Securities

Medicenna Therapeutics (MDNA.TO) has finalized the terms of its previously-announced marketed underwritten public offering of securities of the company, being an offering of units at a price to the public of $0.50 per unit, the company said on Tuesday.Each unit will be comprised of one common share of the company and one half of one warrant of the company, each warrant entitling the holder thereof to acquire one common share at an exercise price of $0.65 until the date that is three years following the closing date of the offering, said the company.The company plans to use the net proceeds primarily to advance the clinical and regulatory development of its lead programs (including MDNA11 and MDNA113), to fund working capital and for general corporate purposes.The offering is expected to close on or around May 27, 2026, subject to the satisfaction of customary closing conditions, added the company.

Medicenna Therapeutics Launches Marketed Public Offering Of Securities

Medicenna Says First Patient Dosed in NEO-CYT Study

Medicenna Therapeutics (MDNA.TO) reported Tuesday that the first patient has been dosed in a Phase 1b trial evaluating its candidate MDNA11, in patients with stage 3 melanoma.The NEO-CYT study will evaluate MDNA 11 with an immunotherapy combination of nivolumab, with or without ipilimumab, as neoadjuvant immunotherapy before surgery in earlier-stage melanoma patients.The rationale is that these patients' immune systems may be more amenable to immunotherapy and more likely to benefit from treatment, Medicenna said."Dosing the first patient in the NEO-CYT study represents an important milestone in the continued clinical development of MDNA11 and expands our evaluation of this next-generation IL-2 Superkine into the neoadjuvant setting," said Dr. Nageatte Ibrahim, Medicenna chief medical officer."MDNA11 has already demonstrated encouraging anti-tumor activity and a manageable safety profile in heavily pretreated patients with advanced metastatic cancers in the ongoing ABILITY-1 study. NEO-CYT allows us to evaluate MDNA11 earlier in the treatment paradigm, where the immune system may be more intact and where pathologic response can provide an early and rigorous signal of clinical activity."The trial is being conducted at up to 12 centres in Italy.Medicenna shares closed up $0.03, to $0.66, on Monday on the Toronto Stock Exchange.

Medicenna Therapeutics Presents "Positive" MDNA113 Data at AACR Meeting

Medicenna Therapeutics (MDNA.TO), trading near 52 week lows, on Tuesday presented new "positive" preclinical data from MDNA113, its lead superkine candidate, in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.In a head-to-head non-human primate study, MDNA113 was well tolerated at doses up to 50 mg/kg while a comparator could not be administered a second dose at a fraction of that exposure due to severe toxicity, including evidence of vascular leak syndrome, a statement said.MDNA113 is designed to address the safety and dosing limitations that have constrained first-generation molecules in this class. "Taken together, these data demonstrate that MDNA113 is a first-in-class PD-1 x IL-2 bifunctional with exquisite design that delivers superior tolerability and a significantly wider therapeutic window compared with first-generation approaches," said Fahar Merchant, Medicenna chief executive.Medicenna shares closed down $0.01 to $0.60, and near 52 week lows, on Monday, on the Toronto Stock Exchange.